Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance：a Phase II,Muti-center, Single Arm Study
Conditions
Interventions
Toripalimab + Pemetrexed + Anlotinib
Locations
1
China
Zhou Chengzhi
Guangzhou, Guangdong, China
Start Date
April 1, 2020
Primary Completion Date
April 1, 2022
Completion Date
April 1, 2022
Last Updated
July 23, 2020
Lead Sponsor
Guangzhou Institute of Respiratory Disease
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions